[WEBINAR] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program

The discovery and development of theranostics requires multiple highly secialized skills which have been combined in an managed alliance with COVALAB, OncodesignABX-CRO advanced pharmaceutical services Forschungsgesellschaft serving a premium solution in Nuclear Medicine

Learn more about the innovative platform DRIVE-MRT in this Webinar.

Register today ➡️


CheMatech, Oncodesign, Covalab and ABX-CRO launch DRIVE™-MRT, a premium, complete integrated service offer for radiopharmaceuticals drug discovery and generation

CheMatech (Dijon, France), the European leader in the design, synthesis and supply of chelating agents, ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing in the development and production of custom antibodies and ABX-CRO (Dresden, Germany), the globally leading full-service CRO for molecular imaging and radiotherapy, today announce their partnership. This strategic collaboration will launch the DRIVE™-MRT (Molecular RadioTherapy) solution. This innovative, premium service offer for therapeutic development is unique in nuclear medicine; it encompasses the full drug discovery process of theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimization, preclinical candidate drug generation and IND, to the design and management of clinical trials.

Read the PDF

EANM 2018

CheMatech will be present at the EANM 2018 in Düsseldorf, Germany from the 13th to 17th of October 2018. We will be very glad to welcome you booth #63 and to present you our new bifunctional chelating agents and GMP services!